1-(2-Methylpropyl)-2-phenylbenzimidazole

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 1-(2-Methylpropyl)-2-phenylbenzimidazole
• 化学式: C₁₇H₁₈N₂
• mdl: MFCD01050200
• 分子量: 250.34
• InChiKey: OORDLVUSBXVJKM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  17.8
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• PHOSPHORESCENT EMITTERS
  申请人：XIA Chuanjun

  公开号：US20100141127A1

  公开（公告）日：2010-06-10

  Heteroleptic compounds containing phenylpyridine and phenylbenzimidazole are provided. The compounds may be used in organic light emitting devices, particularly as emissive dopants in the emissive layer of such devices.

  提供含有苯基吡啶和苯基苯并咪唑的异配合物。这些化合物可用于有机发光器件，特别是作为这些器件发光层中的发射剂。
• HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS
  申请人：Berger Richard

  公开号：US20110028461A1

  公开（公告）日：2011-02-03

  The present invention provides compounds of Formula I, pharmaceutical compositions thereof, and method of using the same in the treatment or prevention of diseases mediated by the activation of β3-adrenoceptor.

  本发明提供了I式化合物，其药物组成物以及使用该组成物的方法，用于治疗或预防通过激活β3肾上腺素受体介导的疾病。
• Combination of an H3 antagonist/inverse agonist and an appetite suppressant
  申请人：van Heek Margaret

  公开号：US20070142369A1

  公开（公告）日：2007-06-21

  The present invention relates to pharmaceutical compositions comprising therapeutic combinations comprising: one or more H 3 antagonists/inverse agonists; one or more appetite suppressants selected from the group consisting of CB 1 antagonists/inverse agonists, sibutramine, phentermine and topiramate; and optionally one or more HMG-CoA reductase inhibitors. The invention also relates to medicaments and kits comprising the pharmaceutical compositions of the present invention, and methods of treating obesity, obesity related disorders and diabetes using the pharmaceutical compositions of the present invention.
• BENZIMIDAZOLE DERIVATIVES AND METHODS OF USE THEREOF
  申请人：Aslanian Robert G.

  公开号：US20100144591A1

  公开（公告）日：2010-06-10

  The present invention relates to compounds of formula (I); compositions comprising the compounds, and methods of using the compounds to treat or prevent pain, diabetes, a diabetic complication, impaired glucose tolerance (IGT) or impaired fasting glucose (IGT) in a patient.
• US8367223B2
  申请人：——

  公开号：US8367223B2

  公开（公告）日：2013-02-05